The global house dust mite allergy treatment market was valued at $1,481.2 million in 2021, and is projected to reach $5,189.3 million by 2031, registering a CAGR of 13.4% from 2022 to 2031. House dust mite allergy is referred to as an allergic reaction to tiny bugs that are present in house dust. The symptoms of house dust mite allergy are sneezing, red or watery eyes, itchy nose roof of mouth & throat, nasal congestion, cough, and swollen blue colored skin under the eye. In case of asthma, allergy results in difficulty in breathing, chest tightness or pain, an audible wheezing sound while exhaling, and shortness of breath.
The growth of the global house dust mite allergy treatment market is majorly driven by increase in-house allergens, rise in awareness among the population about allergic reactions caused due to various types of allergens, and alarming surge in prevalence of allergy diseases. According to the Allergy and Asthma Foundation, in March 2020, it was observed that dust mites are the leading causes of in-house allergies. Furthermore, according to the World Health Organization (WHO), in 2020, it was reported that around 70% of allergic reactions are caused due to house dust mite allergen. In addition, chronic exposure to house dust mites impacts the health of population with asthma, and those who are sensitive and allergic to mites. Thus, the population diagnosed with allergic rhinitis and asthma are more prone to house dust mite allergy. According to the Center for Disease Control and Prevention (CDC), in 2020, it was reported that around 25.2 million population is diagnosed from asthma, globally.
According to the Thermo Fisher Scientific, an American supplier of reagent & consumables, scientific instrument and software, it was reported that around 90% of population diagnosed with allergic asthma are sensitized to house dust mite allergens. Moreover, according to the Center for Disease Control and Prevention, in 2020, it was reported that around 60 million population were diagnosed with allergic rhinitis in the U.S. Thus, increase in prevalence of asthma and rhinitis fuels the growth of the house dust mite allergy treatment market.
However, rise in hygiene practices reduces the occurrence of house dust mite allergy, which hampers the growth of the house dust mite treatment market. Furthermore, lack of proper diagnosis of allergy symptoms caused by house dust mites acts as a key deterrent factor for the global market. On the contrary, increase in awareness among population about various treatments available for allergy diseases is expected to open new avenues for the expansion of the market. This has further encouraged many key players to enter emerging markets, thus offering lucrative opportunities for the market growth.
The global house dust mite treatment market is segmented into treatment, type, route of administration, distribution channel, and region. On the basis of treatment, the market is categorized into antihistamine, immunotherapy, and others. By type, it is bifurcated into prescription and over-the-counter. Depending on route of administration, it is segregated into oral medication and nasal administration. As per distribution channel, it is differentiated into hospital pharmacy, online pharmacy, and retail pharmacy. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Some of the major companies that operate in the global house dust mite allergy treatment market are ALK-Abello A/S, Allergy Therapeutics PLC., Bayer AG, Catalent Pharma Solutions Limited, GlaxoSmithKline Plc., Johnson and Johnson, Merz Pharma GmbH & Co. KGaA, Sanofi, Seqirus UK Limited, and Shionogi & Co. Ltd.
The growth of the global house dust mite allergy treatment market is majorly driven by increase in-house allergens, rise in awareness among the population about allergic reactions caused due to various types of allergens, and alarming surge in prevalence of allergy diseases. According to the Allergy and Asthma Foundation, in March 2020, it was observed that dust mites are the leading causes of in-house allergies. Furthermore, according to the World Health Organization (WHO), in 2020, it was reported that around 70% of allergic reactions are caused due to house dust mite allergen. In addition, chronic exposure to house dust mites impacts the health of population with asthma, and those who are sensitive and allergic to mites. Thus, the population diagnosed with allergic rhinitis and asthma are more prone to house dust mite allergy. According to the Center for Disease Control and Prevention (CDC), in 2020, it was reported that around 25.2 million population is diagnosed from asthma, globally.
According to the Thermo Fisher Scientific, an American supplier of reagent & consumables, scientific instrument and software, it was reported that around 90% of population diagnosed with allergic asthma are sensitized to house dust mite allergens. Moreover, according to the Center for Disease Control and Prevention, in 2020, it was reported that around 60 million population were diagnosed with allergic rhinitis in the U.S. Thus, increase in prevalence of asthma and rhinitis fuels the growth of the house dust mite allergy treatment market.
However, rise in hygiene practices reduces the occurrence of house dust mite allergy, which hampers the growth of the house dust mite treatment market. Furthermore, lack of proper diagnosis of allergy symptoms caused by house dust mites acts as a key deterrent factor for the global market. On the contrary, increase in awareness among population about various treatments available for allergy diseases is expected to open new avenues for the expansion of the market. This has further encouraged many key players to enter emerging markets, thus offering lucrative opportunities for the market growth.
The global house dust mite treatment market is segmented into treatment, type, route of administration, distribution channel, and region. On the basis of treatment, the market is categorized into antihistamine, immunotherapy, and others. By type, it is bifurcated into prescription and over-the-counter. Depending on route of administration, it is segregated into oral medication and nasal administration. As per distribution channel, it is differentiated into hospital pharmacy, online pharmacy, and retail pharmacy. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Some of the major companies that operate in the global house dust mite allergy treatment market are ALK-Abello A/S, Allergy Therapeutics PLC., Bayer AG, Catalent Pharma Solutions Limited, GlaxoSmithKline Plc., Johnson and Johnson, Merz Pharma GmbH & Co. KGaA, Sanofi, Seqirus UK Limited, and Shionogi & Co. Ltd.
KEY BENEFITS FOR STAKEHOLDERS
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the house dust mite allergy treatment market analysis from 2021 to 2031 to identify the prevailing house dust mite allergy treatment market opportunity.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the house dust mite allergy treatment market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global house dust mite allergy treatment market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Treatment
- Antihistamine
- Immunotherapy
- Other
By Type
- Prescription based drugs
- Over the counter drugs
By Route of administration
- Oral medication
- Nasal administration
By Distribution channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- ALK Abello A S
- Allergy Therapeutics PLC
- Bayer AG
- Catalent Pharma Solutions Limited
- GlaxoSmithKline plc.
- johnson and johnson md&d
- Merz Pharma GmbH an Co. KGaA
- Sanofi
- Seqirus UK Limited
- Shionogi and Co. Ltd.
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY TREATMENT
CHAPTER 5: HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY TYPE
CHAPTER 6: HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
CHAPTER 7: HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY DISTRIBUTION CHANNEL
CHAPTER 8: HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY REGION
CHAPTER 9: COMPANY LANDSCAPE
CHAPTER 10: COMPANY PROFILES
List of Tables
List of Figures
Executive Summary
According to the report, titled, “House Dust Mite Allergy Treatment Market," the house dust mite allergy treatment market size was valued at $1.5 billion in 2021, and is estimated to reach $5.2 billion by 2031, growing at a CAGR of 13.4% from 2022 to 2031. House dust mite allergy is an allergic reaction caused by dust mites, which are present in the house environment. House dust mites can survive in any climatic condition due to their adaptive nature. People who are suffering from asthma and rhinitis may face worsened symptoms on exposure to dust mites. House dust mite allergy can be identified by doctors after physical examination. The skin and blood test named as skin prick test and specific IgE blood test are diagnosis tests for house dust mite allergy.Factors that drive growth of the global house dust mite allergy treatment market share include rise in prevalence of house dust allergy, advancements in R&D activities in the pharmaceutical industry, and surge in demand for antihistamine drug. In addition, rise in prevalence of respiratory diseases such as asthma and allergic rhinitis contributes toward the house dust mite allergy treatment market growth. Allergic disease is ranked as the sixth most common cause of chronic illness in the U.S., which is likely to increase the demand for house dust mite allergy products, thus driving the house dust mite allergy treatment market trends.
Furthermore, market players are focused on manufacturing of different house dust mite allergy products. For instance, in May 2021, Glenmark, a pharmaceutical company, announced the launch of Ryaltris AZ, which is a nasal spray used to relieve symptoms of allergic rhinitis. The allergic rhinitis is caused due exposure to allergen such as house dust mite. Moreover, increase in teenage and younger population who are more prone to house dust mite allergy and surge in need for various antihistamine drugs escalate the market growth.
According to the Journal of Current Allergy and Asthma Reports, in 2020, it was observed that adults and children are more susceptible to house dust mite allergy.
Moreover, rise in disposable income and development of the pharmaceutical sector for manufacturing of anti-allergic drugs are anticipated to drive growth of the house dust mite allergy market. In addition, increase in clinical studies on various types of products to evaluate their safety and efficacy propels the growth of the market.
Furthermore, rise in air pollution increases the sensitivity to respond for allergic reactions, which fuels the growth of the house dust mite allergy treatment market. Increase in number of approval of novel therapies and surge in adoption of immunotherapies for treatment of house dust mite allergic reactions notably contribute toward the market growth. This encourages many key players to enter emerging markets, thus offering them remunerative growth opportunities. The global house dust mite allergy treatment market is segmented into treatment, type, route of administration, distribution channel, and region.
On the basis of treatment, the market is classified into antihistamine, immunotherapy, and other segment. The others segment dominated the market in 2021, and is expected to continue during the forecast period, owing to advancements in R&D activities in the pharmaceutical sector and increase in number of key manufacturers.
Depending on type, the market is classified into prescription-based drugs and over-the-counter drugs. The prescription-based drugs segment was the major contributor in 2021, and is expected to maintain its lead during the forecast period, owing to increase in prevalence of house dust mite allergic diseases and initiatives taken by government and private organization to spread awareness about allergic disease.
By route of administration, the market is bifurcated into oral and nasal segment. The oral administration segment dominated the market in 2021, and is expected to continue during the forecast period, owing to increase in demand for oral route of administration, rise in number of U.S. FDA approvals for drugs, and advancements in R&D activities in the pharmaceutical sector.
As per distribution channel, the market is fragmented into hospital pharmacy, online pharmacy, retail pharmacy, and others segment. The hospital pharmacies segment was the major contributor in 2021, and is expected to maintain its lead during the forecast period, owing to rise in prevalence of allergic diseases, surge in demand for monoclonal antibodies, and initiatives taken by government for advancement of hospital pharmacy.
Europe garnered a major share in the house dust mite allergy treatment market in 2021, and is expected to continue to dominate during the forecast period, owing to rise in prevalence of asthma and allergic rhinitis, increase in in-house dust pollution, presence of key players, and development in R&D activities in pharmaceutical sector in the region.
However, Asia-Pacific is expected to register highest CAGR of 14.4% from 2022 to 2031, owing to increase in prevalence of house dust mite allergic diseases, rise in awareness about spreading knowledge regarding allergens, surge in health care expenditure, and increase in adoption of immunotherapy drugs for the treatment of house dust mite allergy.
Key Findings of the Study
- By treatment, the others segment was the highest contributor to the market in 2021.
- On the basis of type, prescription-based drugs segment dominated the market in 2021.
- Depending on route of administration, the oral medication segment exhibited the highest growth in 2021, and is expected to continue this trend during the forecast period.
- As per distribution channel, hospital pharmacy was the prominent segment in 2021.
- Region wise, North America garnered the largest revenue share in 2021, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.
Companies Mentioned
- Alk Abello a S
- Allergy Therapeutics plc
- Bayer AG
- Catalent Pharma Solutions Limited
- GlaxoSmithKline plc.
- Johnson and Johnson Md&D
- Merz Pharma GmbH An Co. Kgaa
- Sanofi
- Seqirus UK Limited
- Shionogi and Co. Ltd.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 245 |
| Published | June 2022 |
| Forecast Period | 2021 - 2031 |
| Estimated Market Value ( USD | $ 1481.2 million |
| Forecasted Market Value ( USD | $ 5189.3 million |
| Compound Annual Growth Rate | 13.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
